By Chris Wack Regenxbio said Tuesday that the U.S. Food and Drug Administration has granted a regenerative medicine advanced therapy designation for RGX-121, an investigational one-time AAV. | May 23, 2023
RMAT recognizes that the preliminary clinical evidence from RGX-121, a potential one-time AAV Therapeutic, indicates the potential to address unmet medical needs for MPS II RMAT designation is for. | May 23, 2023
ROCKVILLE, Md., May 22, 2023 /PRNewswire/ REGENXBIO Inc. today announced that it will present in a fireside chat and panel as well as host one-on-one investor meetings at the Barclays Gene. | May 22, 2023
Research in MPS IVA led by REGENXBIO scientists moving into clinicDonation of NAV® Technology licenses will support development of gene therapies for rare diseasesROCKVILLE, Md., May 16, 2023. | May 16, 2023
ROCKVILLE, Md., April 18, 2023 /PRNewswire/ REGENXBIO Inc. today announced it will present in a fireside chat at Chardan s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit. | April 18, 2023